Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Haemonetics Corp’s stock clocked out at $70.06, up 1.52% from its previous closing price of $69.01. In other words, the price has increased by $1.52 from its previous closing price. On the day, 0.52 million shares were traded. HAE stock price reached its highest trading level at $70.5 during the session, while it also had its lowest trading level at $68.915.
Ratios:
To gain a deeper understanding of HAE’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.97 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.63. For the most recent quarter (mrq), Quick Ratio is recorded 0.99 and its Current Ratio is at 1.62. In the meantime, Its Debt-to-Equity ratio is 1.56 whereas as Long-Term Debt/Eq ratio is at 1.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on February 07, 2025, Downgraded its rating to Underperform and sets its target price to $68 from $95 previously.
On December 06, 2024, JP Morgan started tracking the stock assigning a Overweight rating and target price of $116.
Raymond James Upgraded its Outperform to Strong Buy on November 08, 2024, while the target price for the stock was maintained at $120.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 12 ’25 when Strong Stewart W bought 708 shares for $71.46 per share.
Strong Stewart W bought 7,705 shares of HAE for $538,580 on Jun 04 ’25. On Jun 02 ’25, another insider, Strong Stewart W, who serves as the Officer of the company, bought 2,835 shares for $67.47 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HAE now has a Market Capitalization of 3365766400 and an Enterprise Value of 4340752896. As of this moment, Haemonetics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.12, and their Forward P/E ratio for the next fiscal year is 12.42. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.86. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.47 while its Price-to-Book (P/B) ratio in mrq is 4.12. Its current Enterprise Value per Revenue stands at 3.19 whereas that against EBITDA is 12.194.
Stock Price History:
The Beta on a monthly basis for HAE is 0.37, which has changed by -0.18058479 over the last 52 weeks, in comparison to a change of 0.092761636 over the same period for the S&P500. Over the past 52 weeks, HAE has reached a high of $94.99, while it has fallen to a 52-week low of $55.30. The 50-Day Moving Average of the stock is 6.70%, while the 200-Day Moving Average is calculated to be -2.68%.
Shares Statistics:
It appears that HAE traded 613.17K shares on average per day over the past three months and 499310 shares per day over the past ten days. A total of 48.22M shares are outstanding, with a floating share count of 47.37M. Insiders hold about 1.38% of the company’s shares, while institutions hold 114.59% stake in the company. Shares short for HAE as of 1748563200 were 4118270 with a Short Ratio of 6.72, compared to 1745971200 on 4353951. Therefore, it implies a Short% of Shares Outstanding of 4118270 and a Short% of Float of 11.399999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Haemonetics Corp (HAE) reflects the combined expertise of 10.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $1.17, with high estimates of $1.24 and low estimates of $1.09.
Analysts are recommending an EPS of between $5.06 and $4.81 for the fiscal current year, implying an average EPS of $4.87. EPS for the following year is $5.64, with 8.0 analysts recommending between $5.85 and $5.4.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $305.3M. It ranges from a high estimate of $330.81M to a low estimate of $295.82M. As of the current estimate, Haemonetics Corp’s year-ago sales were $336.17MFor the next quarter, 10 analysts are estimating revenue of $321.74M. There is a high estimate of $345.47M for the next quarter, whereas the lowest estimate is $313.1M.
A total of 10 analysts have provided revenue estimates for HAE’s current fiscal year. The highest revenue estimate was $1.39B, while the lowest revenue estimate was $1.29B, resulting in an average revenue estimate of $1.31B. In the same quarter a year ago, actual revenue was $1.36BBased on 8 analysts’ estimates, the company’s revenue will be $1.4B in the next fiscal year. The high estimate is $1.45B and the low estimate is $1.38B.
